The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Subscribe To Our Newsletter & Stay Updated
